Neuropsychological Dysfunction among HIV Infected Drug Abusers.
Human immunodeficiency virus (HIV) has been documented to cause direct and indirect central nervous system dysfunction that can be observed as a progressive decline in neuropsychological functioning in a large proportion of persons with HIV and AIDS. Neuropsychological decline in individuals with HIV is characterized by cognitive and motor slowing, attentional deficits, executive dysfunction and memory impairment (characterized by intact recognition and deficits in learning and delayed recall). Dementia occurs in a relatively small proportion of HIV infected individuals, though milder NP deficits are observed in 30-50% of persons with advanced disease. Recent evidence suggests that drug users, especially stimulant users, are at risk for accelerated progression of their HIV disease, including a greater risk of neuropsychological dysfunction. Methamphetamine may potentiate HIV Tat protein mediated neurotoxicity giving rise to striatal proinflammatory cytokine stimulation and activation of redox-regulated transcription factors. Oxidative stress due to mitochondrial dysfunction is another candidate process underlying the synergistic effects of stimulant use and HIV. Damage to neurotransmitter systems including the dopaminergic, serotonergic and glutamatergic systems which are affected by both stimulant use and HIV is an alternate explanation. Methamphetamine has also been shown to impede the effectiveness of HAART, which could then in turn allow for more rapid HIV disease progression. A greater prevalence of psychiatric disorders, particularly mood, anxiety and substance use disorders are also observed in HIV positive samples relative to the general population. The changing nature of the HIV pandemic is an ongoing challenge to investigators and clinicians working in this field. Emerging issues requiring additional attention are study of the interactive effects of normal aging and HIV on neurocognition as well as study of the effects of co-infection with Hepatitis C.
Durvasula
Ramani S
RS
California State University, Los Angeles.
Hinkin
Charles H
CH
AIDS. 2000 Sep;14 Suppl 2:S8-17
11061637
Neurology. 1990 Feb;40(2):197-203
2405289
AIDS. 2004 Jan 1;18 Suppl 1:S19-25
15075494
J Neurovirol. 2003 Apr;9(2):205-21
12707851
Soc Psychiatry Psychiatr Epidemiol. 1989 Jan;24(1):12-6
2496472
J Infect Dis. 2003 Dec 15;188(12):1820-6
14673760
Neurology. 2002 Dec 24;59(12):1944-50
12499488
Am J Psychiatry. 1993 Feb;150(2):309-15
8422083
J Neuroimmunol. 2004 Feb;147(1-2):6-8
14741417
Neuropsychology. 1999 Apr;13(2):306-16
10353380
J Clin Exp Neuropsychol. 2003 Oct;25(7):893-903
13680438
Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S38-44
16265612
Neurology. 2005 Apr 26;64(8):1343-7
15851720
Am J Epidemiol. 1992 Dec 1;136(11):1338-48
1362630
J Neurosci. 2001 Dec 1;21(23):9414-8
11717374
Neurology. 2001 Jan 23;56(2):257-60
11160967
J Int Neuropsychol Soc. 2000 Mar;6(3):336-47
10824505
J Subst Abuse Treat. 2003 Jun;24(4):323-30
12867206
J Neuropsychiatry Clin Neurosci. 1998 Summer;10(3):320-9
9706540
Neurology. 1993 Oct;43(10):2099-104
8413973
Am J Psychiatry. 1994 Jul;151(7):1055-62
8010364
Exp Neurol. 2003 Jan;179(1):60-70
12504868
J Clin Exp Neuropsychol. 1989 Oct;11(5):763-73
2808663
Am J Psychiatry. 1995 Apr;152(4):551-4
7694903
J Int Neuropsychol Soc. 1995 Nov;1(6):575-80
9375245
Am J Psychiatry. 2004 Feb;161(2):249-54
14754773
AIDS. 2005 Oct;19 Suppl 3:S72-8
16251831
J Consult Clin Psychol. 1990 Feb;58(1):22-30
2181001
Clin Infect Dis. 2006 May 15;42(10):1449-54
16619159
Mil Med. 1990 Feb;155(2):76-80
2106656
AIDS. 2004 Jan 1;18 Suppl 1:S75-8
15075501
J Nucl Med. 1996 Jul;37(7):1133-41
8965184
Neurology. 2004 Mar 23;62(6):957-62
15037699
Neurology. 2000 Mar 28;54(6):1344-9
10746608
J Acquir Immune Defic Syndr. 2002 Oct 1;31 Suppl 2:S62-9
12394784
Ann Intern Med. 1987 Dec;107(6):828-36
3688675
J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):180-7
7626961
J Clin Exp Neuropsychol. 2006 Apr;28(3):383-404
16618627
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15647-52
16227428
AIDS. 2004 Jan 1;18 Suppl 1:S49-59
15075498
Neurology. 1992 Oct;42(10):1924-30
1407574
Psychoneuroendocrinology. 1999 Aug;24(6):657-77
10399774
Arch Gen Psychiatry. 1989 Aug;46(8):682-9
2751402
J Addict Dis. 2008;27(2):11-7
18681187
J Neuropsychiatry Clin Neurosci. 2003 Summer;15(3):317-25
12928507
J Int Neuropsychol Soc. 2004 Jan;10(1):1-14
14751002
AIDS Behav. 2006 Mar;10(2):185-90
16477511
Arch Neurol. 1992 Nov;49(11):1169-75
1444884
J Int Neuropsychol Soc. 1995 May;1(3):231-51
9375218
J Stud Alcohol. 1995 Nov;56(6):642-53
8558896
J Clin Exp Neuropsychol. 2000 Feb;22(1):16-24
10649542
J Natl Med Assoc. 1998 Nov;90(11):665-74
9828581
Arch Gen Psychiatry. 1990 Jun;47(6):527-31
2350205
N Engl J Med. 1985 Dec 12;313(24):1493-7
2999591
AIDS. 2001 Sep 28;15(14):1898-9
11579260
Arch Gen Psychiatry. 1991 Feb;48(2):124-30
1671198
J Int Neuropsychol Soc. 2001 Jan;7(1):20-6
11253838
Am J Psychiatry. 1995 Aug;152(8):1222-4
7625478
Brain. 2004 Nov;127(Pt 11):2452-8
15319273
J Neuropsychiatry Clin Neurosci. 1993 Summer;5(3):254-9
8369633
J Acquir Immune Defic Syndr (1988). 1993 May;6(5):503-11
8483113
J Clin Epidemiol. 2001 Dec;54 Suppl 1:S35-43
11750208
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Nov;25(8):1523-36
11642652
J Clin Exp Neuropsychol. 2001 Apr;23(2):149-63
11309669
J Int Neuropsychol Soc. 2000 Mar;6(3):322-35
10824504
Neurology. 1991 Oct;41(10):1608-16
1922803
J Magn Reson Imaging. 1999 Oct;10(4):521-6
10508318
Neurology. 1997 Jan;48(1):223-30
9008522
Gen Hosp Psychiatry. 1991 Jan;13(1):4-8
1993519
Arch Gen Psychiatry. 2001 Aug;58(8):721-8
11483137
Compr Psychiatry. 1997 May-Jun;38(3):146-54
9154370
J Clin Exp Neuropsychol. 2006 Jan;28(1):29-42
16448974
J Clin Epidemiol. 2001 Dec;54 Suppl 1:S44-52
11750209